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Background: Pulmonary thromboembolism (PTE) is one of the major causes of sudden 
unexpected death. PTE frequently presents with nonspecific manifestations which makes its 
clinical diagnosis difficult, resulting in a high fatality rate.  
Objectives: The main objective of this study was to determine the prevalence of PTE in 
a series of forensic autopsies. Other aims were to describe the clinical characteristics, 
demographic data and risk factors present in PTE deaths.  
Methods: This study was carried out retrospectively, and all the forensic expert reports 
of the 11 113 autopsies performed in a 5-year period (from 1st January 2005 to 31st 
December 2009), in Northern Portugal (Main Branch and Offices of the National Institute of 
Legal Medicine Porto, Portugal), were reviewed. Those who had findings of PTE were 
selected and the data collected was inserted into a database.  
Results: PTE was found in 106 cases (1% of the total autopsies). The average age of the 
patients was 59,5 ±17 years, ranging from 20 to 92 years. The female-male ratio was 1.5: 1. 
Regarding the time of death, 41% occurred between 6am-12am with a peak in Autumn 
(32,1%) and a minimum in Summer (18,9%). Emboli were found preferentially bilaterally 
(70,8%) with pulmonary infarct in 22% of cases. The most frequent associated conditions 
were cardiovascular diseases (51%), immobilization (43,4%), BMI≥ 25 (37%,), systemic 
hypertension (34%), psychiatric disorder (33%), previous trauma (22,6%), pulmonary 
diseases (22,6%), diabetes mellitus (21%), infection (18%), previous surgery (16%) and 
chronic venous disease (16%). Antemortem suspicion of PTE was present in 5 cases. 
Symptoms prior to death were present in 66% with the most associated symptoms being 
nonspecific (50%), dyspnea (44,3%), alteration of mental status (40%) and thoracic pain 
(30,8%). After the appearance of symptoms, 65,7% died within 24 hours. Medical care was 
sought by 37,3% of patients in the previous two weeks.  
Conclusions: PTE presented without antemortem suspicion in the majority of cases 
despite the frequent presence of prodromal symptoms and seek of medical care in the days 
prior to death. This highlights the importance of sensitizing physicians to the identification of 
PTE and to its prevention by applying appropriate prophylaxis in high-risk patients. 
 





Venous thromboembolic disease (VTD) is considered a major health problem and its 
clinical manifestations include among others deep venous thrombosis (DVT) and pulmonary 
thromboembolism (PTE). The importance of VTD is related to the high mortality resulting 
from PTE and the acute and long-term morbidity of DVT.  
VTD is the result of a disruption of the normal hemostasis; thrombus formation results 
from venostasis, hypercoagulability and endothelial injury, known as the Virchow’s triad.
1
 
PTE is one of the major causes of sudden unexpected death and usually results as a 
sequel of DVT in the lower limbs or pelvic venous system, frequently presenting with 
nonspecific manifestations.
2, 3
 This non specific manifestations makes its clinical diagnosis 
difficult, and despite the availability of sophisticated laboratory techniques, it is a cause of 
frequent misdiagnosis that leads to fatal outcome.
3-5
 Although it can have a recurrent course
6
, 
approximately half of the fatal cases die within one hour after their clinical onset
7
, and 
approximately 25% presents initially as sudden unexpected death.
8
 These sudden deaths can 
be associated with sudden cardiac chock induced by massive PTE, which leads to progressive 
pulmonary hypertension and right ventricular dysfunction.
7, 9
 In a high number of sudden 
unexpected deaths, only autopsy could prove their true diagnosis.
7, 10
 It’s important to search 
for and recognize associated risk factors because the identification of high risk situations 
could prevent, by implementing appropriate prophylaxis, the associated high mortality rate. 
Therefore, it is useful to further assess the frequency and characteristics of PTE in autopsy 
with the intent of identifying specific situations in which an antemortem clinical diagnosis is 
often missed. 
The most frequent suggested PTE acquired risk factors are immobilization, increasing 
age, pregnancy, puerperium, oral contraceptives, long-haul air travels, trauma, surgery, 
obesity, heart diseases, malignancies and paraneoplastic states.
1, 6, 11, 12
 Hyperlipidemia, 
alcohol abuse/withdrawal, infection, environmental agents, vasculitis or dehydrated states are 
less recognized, and the exact factors that influence the development of acute episodes remain 
unclear.
1, 6, 11, 12 
Often, the precipitating event cannot be recognized, and it could be a 
multifactorial etiology or the result of a inherited thrombophilic disorder.
1, 13
 
In previous autopsy studies the global prevalence ranges from 1% to 4%.
14, 15 
The main objective of this study is to evaluate the prevalence of pulmonary 
thromboembolism in the forensic autopsies performed in Northern Portugal (Main Branch and 




Additionally, it has also the aim to determine the clinical characteristics, demographic data 
and risk factors of PTE sudden unexpected death. 
Material and Methods 
This study was carried out retrospectively, and all the forensic expert reports of the 
autopsies performed during a 5-year period (from 1st January 2005 to 31st December 2009), 
in Northern Portugal (Main Branch and Offices of the National Institute of Legal Medicine 
Porto [INML], Portugal), were reviewed.  In order to select those who had findings of PTE as 
the major cause of death, the keyword “thromboembolism” was inserted in the informatics 
database MedLeg-Pat of the North Branch of INML. From a total of 11.113 reports, 106 cases 
were selected based on macroscopically and/or microscopically documented PTE. 
The autopsy routine includes analysis of the topography and in loco alterations, 
followed by dissection as well as macroscopic and microscopic analyses of the organs. The 
extremities’ veins are not routinely dissected. 
The forensic expert reports with the circumstances of death, autopsy findings, and 
clinical records were reviewed when available, in order to search for conditions or events that 
represented identifiable risk factors for the development of PTE. These findings were 
collected by an investigator and inserted into a computer database.  
In this study the definition of sudden unexpected death used was according to 
commonly accepted criteria, as when an individual dies suddenly from natural causes within 
24 hours since symptoms appear, in an individual who was apparently healthy or one whose 
disease was not severe enough in order to predict such an abrupt outcome.
13, 16, 17
 
Pulmonary embolism was considered the main cause of death when organized thrombi 
with gross features consistent with pre-mortem formation were observed to obstruct the 
majority of the pulmonary arterial tree, either in the pulmonary artery trunk or in the proximal 
right or left pulmonary arteries formed from the bifurcation of the main trunk, and other 
causes of death were definitely excluded. Emboli derived from the bone marrow, fat, tumor or 
amniotic fluid were excluded from this analysis. 
The incidence of PTE found in the autopsies was calculated. Age, gender, place and 
time of death (between 0-6 am, 6am-12am, 12am-6pm and 6pm-12pm), and season of the 
year when the death occurred, were reviewed. Risk factors for thrombotic disease were also 
investigated: recent surgery or trauma (previous 8 weeks), immobilization, cardiovascular 




mellitus, neoplastic diseases, DVT, pulmonary diseases, presence of infection, pregnancy or 
puerperium, dislipidemia, digestive diseases, chronic venous disease, chronic alcoholism and 
personal or family history of thrombophilic disorders. Body mass index (BMI) was classified 
according to the World Health Organization criteria: obesity was defined as BMI > 30 kg/m
2
 
and overweight between 25 and 29,9 kg/m
2
. Psychiatric profiles (including chronic 
alcoholism and drug addiction according to DSM IV)
18
 as well as antipsychotic drug use, 
medications taken in the last two months (including anticoagulant therapy and oral 
contraception) were also investigated. 
The need to visit an emergency department or to seek medical care in the previous two 
weeks; the identification of symptoms prior to death and the period of time elapsed between 
the beginning of symptoms and death; existence or clinical suspicion of the diagnosis of 
pulmonary embolism prior to death; presence of a typical clinical triad of prearrest clinical 
factors (overt dyspnea, alteration of mental status or syncope and shock) and death witnessed 
by a health professional were also analyzed. 
Regarding post-mortem findings, we studied the localization and source of the emboli 
and the presence of pulmonary infarcts as well as histopathological and toxicological analysis, 
when performed. Genetic studies were not performed. 
In order to guarantee the protection of the dead patients’ identity, each case file was 
codified with numbers. 
Statistical analysis was performed using SPSS (version 19). Statistical significance was 
set at p values less than 0.05. Mean values were compared by the Student t test or Mann-
Whitney method appropriately. For the comparative study of proportions, the Chi-Squared 
test was utilized. 
Results  
The North Branch of the National Institute of Legal Medicine includes the Main Branch 
in Porto and 9 Offices, with some of them located in more rural areas, and serves an estimated 
population of 3.637.889 inhabitants. Of the 11 113 autopsies performed during the 5-year 
study period, fatal PTE was found in 106 cases (1%). The annual percentage of fatal PTE was 
1%. 
The average age of the patients was 59,5 ±17 years, ranging from 20 to 92 years (20 to 




two sexes was similar (p=0,730). There were no deaths from PTE in patients under the age of 
20 years. The distribution of cases according to age and sex is shown in Figure 1.  
The female-male ratio was 1.5: 1, with fatal PTE being found in 63 women (59,4%) and 
43 men (40,6%). 
Regarding the time of death, 41% (n=40) occurred between 6am-12am; 26,5% (26 
cases) and 24,5% (n=24) died between 12am- 6pm and  6pm- 12pm, respectively. Only 8,2% 
of deaths (n=8) occurred between 0-6am. 
The seasonal variation of PTE found in the autopsies is shown in Figure 2. In relation to 
the different seasons, the summer had the lowest number of cases (n=20; 18,9%), while the 
autumn had the highest (n=34; 32,1%), with the spring and winter registering the same 
number of cases (n=26; 24,5%).  
Regarding the place of death, 43 (41%) occurred at home, 7 (6.7%) in public places, 55 
(52.4%) in the hospital (or during the transfer to a medical institution) of which 17 cases were 
hospitalized, 4 in a psychiatric unit.  
Emboli were found preferentially bilaterally (70,8%); the main right pulmonary artery 
accounted for 15,1% (n=16) and the main left pulmonary artery and the arterial main trunk 
6,6% (n=7) each. In one case the emboli were not detected in the main vessels. Pulmonary 
infarct was found in 15 cases (22%) of a total of 69 cases. The histopathological analysis was 
performed in 63 cases (60%), and of those, only 2 cases were not confirmed histologically.  
The source of the emboli was investigated in 22 cases (21%). 22,4% (n=12) of the emboli that 
occurred in the context of fatal PTE originated from the legs deep veins; 2 cases originated in 
the pelvic veins, 1 in the inferior vena cava and 1 in the cardiac chambers. The remaining six 
cases had unknown origin. Systematic microscopic evaluation of the thrombi and the leg’s 
veins was not done. 
Toxicological analysis was made in 76,4% of cases (n=81), with positive results in one 
third. The main substances found were antipsychotics (n=13), alcohol (n=13), 
benzodiazepines (n=6) and antidepressants (n=5). One case was positive to drugs of abuse.  
Differences were found concerning the histopathological and toxicological analyses 
performed in the Main Branch and the Offices as well as relative to examining the source of 
the emboli. In the Main Branch the histopathological analysis was performed in 69.6 % of 
cases (n=39), comparatively to 52% in the Offices (p=0,063). As for toxicological analysis 
statistically significant differences were found, with the Main Branch performing it in 90,9% 




found relative to the search of emboli’s source: 30,4% in the Main Branch comparatively to 
10% in the Offices (p<0,01). 
From the 106 cases, 97 were found to have an underlying identifiable predisposing risk 
factor. The most frequent associated conditions were cardiovascular diseases (51%), 
immobilization (43,4%), systemic hypertension (34%), previous trauma (22,6%), pulmonary 
diseases (22,6%), diabetes mellitus (21%), infection (18%), previous surgery (16%) and 
chronic venous disease (16%). Other associated conditions are described in table 1. In 9 of the 
cases there was no remarkable evidence of an underlying risk factor.  
The majority of patients displayed more than one underlying condition. On average, 
they presented between 2 to 3 underlying conditions, with minimum of 0 to a maximum of 6. 
One case of metabolic lipid myopathy and one case of rheumatoid arthritis were found. Only 
2 cases were known to be taking oral contraceptives and only one case was in the puerperium 
(15 days postpartum).  None of the women was pregnant and neither long-haul travel nor 
pathological antecedents or family history of thrombophilic disorders were found. 
Previous DVT was known in 3 cases while 7 cases were actually affected by DVT. 
Only 1 of those 7 was diagnosed, and no treatment was instituted.  
The post-operative emboli occurred on the 10th day (median, range 1 to 60 days) after 
surgery and on the 15th day (median, range 1 to 60 days) after the trauma event.  
The body mass index (BMI) ranged from 15,5 to 53,3 kg/m
2
. Of a total of 78 cases, half 
had a BMI ≥ 25 kg/m
2




Concerning psychiatric disorders, we found 35 diagnosed cases (33%: 16 males; 19 
females), 14 cases in the Offices and 21 cases in the Main Branch; 13 of them were medicated 
with antipsychotics (2 in the Offices and 11 in the Main Branch). Four were known to be 
under their effect with therapeutical concentrations at the moment of death. From the 13 
cases, none had previous DVT and 3 had no additional risk factors.  More details on table 2.  
The percentage of patients taking medication in the previous 2 months was 95% (78 of 
82). 
Four patients were receiving anticoagulant prophylaxis and 3 were taking therapeutic 
anticoagulant doses by the time of death, 2 of whom due to clinical suspicion of PTE and the 
other for previous PTE. Antemortem suspicion or diagnose of PTE occurred in 5 of the 
patients which had PTE as cause of death. Previous PTE was known in 2 cases (6 months and 




3 had previous fracture of lower limbs, (2 of which underwent surgery), and 1 was in the 14th 
day after stroke.  
Symptoms prior to death were found in 70 cases (66%), and from those, 47,1% (n=33) 
died within the first hour, 18,6% (n=13) in the first 24 hours and 34,3% (n=24) had symptoms 
in the previous days. The most frequent associated symptoms were dyspnea (44,3%), 
alteration of mental status (40%), thoracic pain (30,8%), legs pain (14,3%) and shock 
(11,4%). Nonspecific symptoms were seen in half of the patients. One case reported the 
occurrence of hemoptysis. No differences were found regarding the occurrence of prodromal 
symptoms in hospitalized patients (58,8%) and outpatients (68,2%) (p=0,454). 
Regarding the presence of prearrest symptoms, only 20% were found to have more than 
one typical prearrest symptom (dyspnea, alteration of mental status and shock). 
The death was witnessed by a health professional in about half of the cases.  
Forty patients sought medical care (out-of-hospital and in-hospital) in the two weeks 
prior to death. Of them, 15 had typical clinical symptoms and history of PTE or DVT though 
those conditions were not suspected, and none had initiated appropriated therapy. Other 
conditions present were 3 cases with urinary tract infection, 2 with abdominal pain and 2 
cases of psychotic crisis with psychomotor agitation. Some of those cases are described on 
table 3. 
Discussion 
The prevalence of PTE is mostly influenced by the studied population (general 
population versus hospitalized population), population characteristics (as age and underlying 
conditions) and also according to the techniques performed in the autopsy. Our study is 
settled in forensic autopsies, which might lead to distinct results when compared to autopsies 
performed in a hospital setting, the latter’s showing higher prevalence, because hospitalized 
patients are more likely to have more risk factors than the general population surveyed in the 
forensic setting. In our findings PTE accounted for 1% of deaths, which is within the previous 
reported range in autopsies studies, such as 1,2% obtained by Lucena et al
13




The age distribution we are reporting show that, despite the presence of a relationship 
between advancing age and pulmonary embolism (with age being an independent risk factor, 
as stated in others studies), there is an important raise in the number of cases in the middle 
age, already seen in other series too.
3, 5, 7, 14




probably associated with the increase in associated risk factors like cardiovascular diseases, 
and to the combination of reduced mobility and muscle tone with degenerative vascular 
changes that confer increased morbility.
19 
Pulmonary embolism was more common in women, in agreement with the results 
found by other studies.
5, 9, 20
 Others show no sex difference or a male predominance.
8, 21
  
PTE deaths in young, apparently healthy persons may reflect an underlying coagulation 
defect leading to hypercoagulability, which, if there is no identifiable cause, could represent 
an underlying thrombophilic disorder. These disorders can be of inherited or acquired nature, 
and its determination could be relevant to the decedent’s family. Genetic tests were not 
performed in this study, and its application on routine autopsies is not recommended due to its 




We found that 41 % of the deaths occurred between 6 and 12 am, which suggest that the 
morning hours are more risky for the occurrence of PTE. This is probably related to the 
existence of a circadian pattern involving thrombus formation, with a morning peak in several 
pro-coagulation parameters.
22, 23 
Thrombus detachment is also more favorable in the first 
hours of morning until noon, due to a series of physiologic mechanisms.
23
 The awareness of 
these circadian rhythms could be of interest concerning the best approach to prevention and 
treatment of PTE events. 
The seasonal variation in PTE deaths has been studied for a while; however, those 
attempts haven’t reached definite conclusions yet. Some studies found that it was more 
frequent in the winter, maybe related to the cold weather, while others found peaks in autumn 
and spring.
11, 23, 24 
The shape of our graph showing the seasonal variation is similar to what 
Green and Edwards found, with a peak in autumn and a reduction in summer cases.
11, 20 
The 
reason for this finding is not clear, while there is still some indication that the weather could 
be implicated in regions where the climatic seasons are well defined.
24, 25
 
The microscopic examination of the thrombi and veins was not performed, and on the 
literature there are only a few forensic studies on thrombus age estimation; despite that, 
forensic pathologists should always search the emboli’s source and estimate how old the 
thrombi are.
2, 26 
Searching for the source is important, and a detailed examination including 
the crural veins could help to highlight the conditions and risk factors for PTE.
7
 It could be an 
important medico-legal issue to know if a pulmonary embolus arose prior to, or subsequent to 
some traumatic event, and the best method is to examine and to date the residual thrombus.
4 




(21%). Most PTE arise from DVT that occur in the deep leg veins, proximal to and including 
the popliteal veins.
4, 10, 20
 Despite the impossibility to sometimes find the source of the emboli, 
the absence of thrombi in the deep leg veins does not exclude them, as the thrombi can be 
dislodged, be involuted by organization or be submitted to therapeutic or postmortem 
thrombolysis, leaving no residual disease.
4, 6, 20, 27
 Cardiac thrombi are related to fatal PTE, 
mainly in patients with cardiac right chambers dysfunction, as well as large pelvic veins 
thrombi, more frequent following pelvic surgery and trauma.
27
  
The microscopic examination of the emboli is a way to minimize the risk of 
misclassification of the PTE as the main cause of death, and was only performed in 60% of 
the cases. Pulmonary infarction was only seen in 22% of the cases, remaining an infrequent 
finding.  This could be related to the dual perfusion by the pulmonary artery and the bronchial 
artery or to the short period from onset to death.
7, 13 
The most frequent underlying conditions found were in agreement with those 
established in previous studies.
4, 8 
The disease most associated with PTE was cardiovascular 
disease (51%), similarly to the findings of the majority of studies.
25
 Acute infectious illness 
was found in 18% of the cases, with respiratory infection being one of the most often 
associated infectious conditions, together with urinary tract infections, which have recently 
been associated with a transient risk.
14, 27, 28 
The pathophysiology of VTD in the presence of 
acute infection remains to be fully defined, but recent evidence suggest the involvement of 
respiratory viruses capable of infecting endothelial cells and causing a shift from anti-




PTE should also be of concern in trauma patient, especially in those who present 
thoracic discomfort, representing 22,6% in our findings.
27
 Regarding surgical procedures, we 
found 16%, with the emboli occurring mainly in the 10
th
 day after surgery, close to the 13
th
 
day reported by Lindblad et al.
10, 30 
Associated with those two conditions, immobilization is 
present in 43,4% of cases. The thrombus formation can happen due to immobilization even 
for a short time, like car driving, with crural type DVT often associated with bilateral venous 
stasis.
2, 7 
Other factors increasing thrombotic predisposition combine synergistically with 
immobilization for thrombi formation.
7
 
The association between malignancy and PTE is well known, because of the state of 
induced hypercoagulability, however we found cancer in only 9 cases.
7, 12, 14 
Obesity was an 




the findings of previous studies; nevertheless its specific relation to PTE as an independent 
risk factor is still being studied.
13 
We found 33% of the cases having a psychiatric disorder diagnosis, which is in 
agreement with other recent studies.
7, 9, 31, 32 
These studies suggest that antipsychotics drugs 
confer a higher risk for PTE; indeed, in Western countries, PTE has been reported among 
patients treated with antipsychotics.
9, 33 
However some authors state that there is no strait 
relationship between antipsychotics and VTD.
34, 35 
We found some differences according to 
the geographical area: from a total of 13 cases taking antipsychotics, 11 (from 56 PTE cases 
found in the Main Branch) were located in an urban area and only 2 (from 50 from the 
Offices) in more rural regions. This could be related to a more difficult access to medical care 
according to the reality of our rural zones, with fewer patients diagnosed and consequently 
fewer cases medicated. 
To reduce the incidence of PTE, persons at risk must be identified and recent studies, 
such as ours, show a high number of medical conditions like cardiovascular and acute 
infection diseases associated with fatal events. This goes against the old idea that the most 
affected patients were surgical.
8, 13, 14 
This could be related to a higher knowledge of the need 
to prevent VTD in patients submitted to surgery and consequently, to its targeted prevention 
with appropriate prophylaxis. Despite the availability of effective prophylaxis and treatment, 
high rates of VTD are still common in hospitalized patients, with untreated acute proximal 
DVT causing clinical PTE in 33-50% of the patients.
4, 14, 36 
It’s urgent to emphasize that high-
risk patients hospitalized for medical conditions should also be provided with prophylaxis, as 
recommended by different guidelines, with an impact in potentially preventable deaths.
8, 14
 
 Clinical symptoms as a method for diagnosis of thromboemboli have low sensitivity.
3 
From the 66% of patients that presented with symptoms, the most frequent was dyspnea 
44,3%, in agreement with previous studies.
13
 Ro et al reports the existence of pre-existing 
symptoms in 65% of cases.
37
 Vague and nonspecific symptoms were present in half of the 
cases and this is an important question because patients without underlying cardiopulmonary 
disease may appear anxious but otherwise well compensated despite an anatomically large 
PTE.
10, 12 




About 65,7% of patients died within 24 hours after the first symptoms, similar to the 
one third of patients that died within 24 hours of admission as reported by Karwinsky and 
Svendsen.
5 





The PTE prearrest symptom triad could be recognizable compared with other causes of 
death, and this could offer an opportunity to treat the patient acutely. According to Courtney 
and Kline
15
, the sequence of prodromal effects is prolonged enough (period of minutes to 
hours) to allow its identification in many cases, with one third of the cases with all 3 
symptoms present, and about a half with 2. However, in our study, a low percentage (20%) 
presented more than 1 symptom of the triad (dyspnea, alteration of mental status and shock). 
It is also important to determine if most of the deaths are witnessed by a health professional, 
because if so, we could intervene rapidly to prevent PTE deaths.
15, 38 
Our results showed that 




It is suggested that most of the cases of fatal PTE might have a subclinical history of 
nonfatal PTE, and that an increasing rate of consulting doctors and proper diagnosis of PTE at 
an early stage might prevent fatal PTE.
7
 In a previous study, PTE patients were five times 
more likely to have been seen by a physician within two weeks of arrest compared to patients 
who died suddenly from other causes; indeed, other authors found that about half of the cases 
with pre-existing symptoms had consulted a doctor
7, 15
 and in our study 40 cases (37,3%) 
sought medical care in the previous two weeks. Other issue of concern is that in our series, 
almost 24  from those 40 cases (60%) presented symptoms that could raise the suspicion of 
PTE or the need to preventing thrombotic events by applying appropriate prophylaxis, but 
none had been medicated. Previous studies found one third of patients under the conditions 
mentioned above and others that only 25% of the patients had been suspected of PTE.
7, 15
 
PTE continues to challenge the physicians with great number of cases without 
antemortem diagnosis
27
 and autopsy is still regarded as the diagnostic gold standard.
4
 The 
accuracy of antemortem diagnosis of DVT and PTE is within the range of just 10-30%,
20
 
representing one of the most frequently missed diagnosis in sudden unexpected death.
4, 15 
In 
our series, 95% had absence of clinical antemortem suspicion, in agreement with the 84% 
missed diagnosis reported by Karwinsky and Svendsen
5
 and close to the range of 67% to 91% 
described in the literature.
27
 So, despite the availability of complementary diagnostic means 
there is a general difficulty in diagnosing PTE and this high rate of underdiagnosed PTE is 
probably responsible for the high mortality that results when this condition is forgotten.
27
 
One limitation of our study is that it was done retrospectively, and in different centers, 
so the protocol of autopsy, despite the general rules followed by all, was not completely 
uniform, as we were able to see, with statistically significant differences in the use of 




frequent lack of information regarding previous clinical features, like medication taken and 
pathological antecedents. 
Studies like ours stress the importance of the performance of a complete autopsy with 
the use of classical complementary techniques, like histological analysis, in order to achieve a 
detailed characterization of the population affected by PTE, identifying the specific situations 
that could constitute risk factors.
16
 For that, autopsy diagnosis of PTE sudden unexpected 
death depends on the use of a rigorous protocol in order to not forget any step and its 
application in a uniform manner is essential. 
Final Remarks 
It is important to bear in mind that PTE is an important life-threatening condition in our 
societies and that acute responses are needed after the onset. This implies rapid recognition 
along with identification of the high risk population in order to initiate appropriate 
prophylaxis that has been proven in series of clinical trials to be effective. 
Our study showed a high number of associated medical conditions, and its presence 
should alert physicians to the risk of PTE, because the rate of PTE antemortem suspicion was 
unacceptably low, regarding the presence of prodromal symptoms and seek of medical care. 
As stated before, the initial manifestation of PTE in 25% of the patients is sudden 
death.
15
 Recent studies, as ours, showing that fatal PTE can be found in relative healthy 
ambulatory patients in the fourth or fifth decade of life, should lead to more active research 
into the rapid recognition of PTE and its effective prevention.
15, 21 
In order to reach some conclusions regarding the possible association of the use of 
antipsychotics drugs and PTE, concern should raise regarding the identification of those 
specific drugs.  The importance of collecting previous clinical information in clinical records 
or with the family should be stressed.  
Autopsies are essential to study PTE associated risk factors, but to be even more 
effective, we recommend that they should be performed following a strict protocol in PTE 
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Table 1: Characteristics of patients taking antipsychotics drugs 
 
  
Age Sex Diagnosis Antipscychotics Place of 
Death 
31 F Unknown Olanzapine, haloperidol, 
chlorpromazine 
Hospital 
38 F Schizophrenia Levomepromazine, clozapine Hospital 
39 M Psychosis not specified Levomepromazine, chlorpromazine Hospital 
44 M Bipolar disorder, 
chronic alcoholism 
Levomepromazine Home 
50 F Bipolar disorder  Unknown Hospital 
58 F Unknown Haloperidol, cyamemazine Hospital 
62 M Unknown Cyamemazine Home 
64 F Schizophrenia, 
dementia 
Olanzapine, haloperidol Hospital 
66 M Unknown Risperidone Hospital 
78 M Vascular and 
Alzheimer’s dementia 
Quetiapine Hospital 
86 F Unknown Cyamemazine Hospital 
87 M Unknown Melperone Home 




Table 2: Underlying conditions associated with PTE cases.  
Underlying conditions Cases (N / %) Details 
Cardiovascular diseases 54 (51%)  
Immobilization 46 (43%)  
BMI ≥ 25 kg/m
2
 39 (37%)  
Systemic hypertension 36 (34%)  
Psychiatric disease 35 (33%)  
Pulmonary diseases 24 (23%)  
Previous trauma 24 (23%) 18 fractures of lower limbs;1 burn 
injury;1 abdominal blunt trauma 
Diabetes mellitus 22 (21%)  
Infection 19 (18%) 8 respiratory; 4 urinary tract 
Previous surgery 17 (16%) 9 orthopedic 
Chronic venous disease 17 (16%) 3 previous DVT 
Digestive diseases 14 (13%)  
Dislipidemia 11 (10%)  
Neoplasia 9 (8,5%) 2 melanomas; 2 gastric cancers 






Table 3: Characteristics of patients who sought medical care in the last 2 weeks before PTE. 
Age Sex Symptoms Diagnosis Treatment 





33  F Left leg pain Thrombophlebitis Antibiotics, NSAID* 
33  F Palpitations, thoracic 
discomfort, dyspnea, 
fatigue  
Sinus tachycardia Benzodiazepines, beta-
blocker 
35  F Convulsive crises (3) Depression Fluid therapy, 
antidepressants 
36  F Leg pain and swelling Muscular pain None 

















75 F Dyspnea, fatigue Respiratory 
infection, anemia 
Antibiotics 







Figure 1:  Age and sex distribution of PTE cases. 
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Refrain from using online references if possible. When referring to internet sources, for example
Wikipedia, please state so clearly, and indicate if this information can be checked and on which date
you visited this online source.
Reference style
Text: Indicate references by superscript numbers in the text. The actual authors can be referred to,
but the reference number(s) must always be given.
List: Number the references in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
2000;163:51–9.
Reference to a book:
2. Strunk Jr W, White EB. The elements of style. 3rd ed. New York: Macmillan; 1979.
Reference to a chapter in an edited book:
3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 1999, p. 281–304.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6
should be listed followed by "et al." For further details you are referred to "Uniform Requirements
for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 1997;277:927–934) (see also
http://www.nlm.nih.gov/bsd/uniform_requirements.html).
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include these within the body of the article. This can be done in the same way
as a figure or table by referring to the video or animation content and noting in the body text where it
should be placed. All submitted files should be properly labeled so that they directly relate to the video
file's content. In order to ensure that your video or animation material is directly usable, please provide
the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and
animation files supplied will be published online in the electronic version of your article in Elsevier
Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your
files: you can choose any frame from the video or animation or make a separate image. These will
be used instead of standard icons and will personalize the link to your video data. For more detailed
instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions.
Note: since video and animation cannot be embedded in the print version of the journal, please
provide text for both the electronic and the print version for the portions of the article that refer to
this content.
Supplementary data
Elsevier accepts electronic supplementary material to support and enhance your scientific research.
Supplementary files offer the author additional possibilities to publish supporting applications, high-
resolution images, background datasets, sound clips and more. Supplementary files supplied will be
published online alongside the electronic version of your article in Elsevier Web products, including
ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is
directly usable, please provide the data in one of our recommended file formats. Authors should
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submit the material in electronic format together with the article and supply a concise and descriptive
caption for each file. For more detailed instructions please visit our artwork instruction pages at
http://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One Author designated as corresponding Author:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been "spellchecked" and "grammar-checked"
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge)
and in print or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black and white versions of the figures are also supplied for
printing purposes
For any further information please visit our customer support site at http://support.elsevier.com.
AFTER ACCEPTANCE
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. The correct format for citing a DOI is shown as follows (example taken
from a document in the journal Physics Letters B):
doi:10.1016/j.physletb.2010.09.059
When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never
to change.
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in
the e-mail so that authors can download the files themselves. Elsevier now provides authors with
PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or
higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files
will accompany the proofs (also given online). The exact system requirements are given at the Adobe
site: http://www.adobe.com/products/reader/systemreqs.
If you do not wish to use the PDF annotations function, you may list the corrections (including
replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections
quoting line number. If, for any reason, this is not possible, then mark the corrections and any other
comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan
the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing,
completeness and correctness of the text, tables and figures. Significant changes to the article as
accepted for publication will only be considered at this stage with permission from the Editor. We will
do everything possible to get your article published quickly and accurately – please let us have all your
corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one
communication: please check carefully before replying, as inclusion of any subsequent corrections
cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with
the publication of your article if no response is received.
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Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the article
is accepted for publication. The PDF file is a watermarked version of the published article and includes
a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.
Author orders
When your article is published, you can commemorate your publication with printed author
copies of the journal issue, customized full-color posters, extra offprints, and more. Please visit
http://webshop.elsevier.com to learn more.
AUTHOR INQUIRIES
For inquiries relating to the submission of articles (including electronic submission) please
visit this journal's homepage. Contact details for questions arising after acceptance of
an article, especially those relating to proofs, will be provided by the publisher. You
can track accepted articles at http://www.elsevier.com/trackarticle. You can also check
our Author FAQs (http://www.elsevier.com/authorFAQ) and/or contact Customer Support via
http://support.elsevier.com.
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